Navegando por Palavras-chave "octreotide"

Agora exibindo 1 - 2 de 2
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Direct labeling studies of octapeptides with rhenium-188
    (R Oldenbourg Verlag, 2003-01-01) Faintuch, B. L.; Pereira, NPS; Faintuch, Salomao [UNIFESP]; Muramoto, E.; Silva, CPG; CNEN; Universidade Federal de São Paulo (UNIFESP)
    The somatostatin octapeptide lanreotide and octreotide were labeled with rhenium-188 by direct method. the optimization of the labeling, the in vitro stability of the complexes and the biodistribution were evaluated. Labeling efficiency was generally greater than 95%. the best time for reaction was 2 hours. Re-188-lanreotide gave better radiochemical yields than Re-188-octreotide, and it was stable for a longer time (24 vs. 4 hours), but the mass of lanreotide had to be larger than that for octreotide (350 vs. 250 mug), and the required ratio between mass of stannous chloride and peptide was also greater for lanreotide. Use of tartrate/phthalate buffer with Re-188-octreotide gave better radiochemical results and showed more labeling stability than the use of acetate/acetic acid buffer. the results of Cys challenge for Re-188-peptides revealed higher chelation strength for Re-188-octreotide than for Re-188-lanreotide for concentrations of cysteine below 1 mM. for a concentration of cysteine of 100 mM the rate of transchelation of Re-188 to cysteine was the same for both peptides. the CD50 value for Re-188-octreotide was 10 mM of cysteine and for Re-188-lanreotide, it was 55 mM.Re-188-labeled peptides were distributed in the gastrointestinal tract or in the kidneys and rapid blood clearance was observed in the first hour. Results indicated that the products can be obtained with high radiochemical purity, appropriate for in vivo studies to assess their efficacy in radioimmunotherapy.
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Pituitary Apoplexy After a Single Dose of Long-Acting Octreotide
    (Lippincott Williams & Wilkins, 2010-01-01) Chang, Claudia Veiga; Felicio, Andre Carvalho [UNIFESP]; Nunes, Vania dos Santos; Carneiro da Cunha-Neto, Malebranche Berardo; Barros de Castro, Ana Valeria; Univ Estadual Paulista; Universidade de São Paulo (USP); Universidade Federal de São Paulo (UNIFESP)
    Pituitary apoplexy (PA) is a rare and potentially life-threatening syndrome resulting from an acute infarction or hemorrhage of the pituitary gland. Although the pathogenesis is not fully understood, some predisposing factors such as pituitary stimulation tests, diabetes mellitus, anticoagulant or antiplatelet aggregation therapy, head trauma, and high blood pressure may play a role in its pathophysiology. Octreotide is the mainstay of medical treatment for acromegaly. the majority of reported complications of octreotide therapy are gastrointestinal. We report the case of a 51-year-old acromegalic woman who developed pituitary apoplexy within the context of high blood pressure and a single dose of long-acting octreotide. Our data suggest that the combination of hypertension and octreotide therapy enhances the risk of pituitary apoplexy.